Major CNV publication cites OGT's CNV service

Oxford, UK – 22 October 2009. OGT is proud to be associated with last week’s Nature publication entitled ‘Origins and Functional Impact of Copy Number Variation in the Human Genome’ (doi:10.1038/nature08516). For the study, OGT, the pioneer of microarray technology, was chosen as the service provider, having delivered data of exceptional quality during evaluation.

“We are delighted to have been selected for the study due to the high quality of the data generated, and to have contributed to the Nature publication. Subsequently, we have generated in excess of 2 billion CNV data points using the Agilent platform and, most importantly, have achieved a consistently high-quality data set,” commented Mike Evans, OGT’s CEO.

Today, Thursday October 22nd, at the 59th annual meeting of the American Society of Human Genetics in Honolulu, Hawaii, OGT is sponsoring the Invited Scientific Session ‘Impact of Structural Variation on Human Disease and Evolution’ which will be reporting on some of the lessons learnt from the most recent large-scale studies, such as HapMap3 and the 1,000 Genomes Project.

Genefficiency, OGT’s high throughput genomic services, combines industry leading platforms, expert people and unparalleled sample processing power, to rapidly deliver high-quality genomic data.

“By providing high sample throughput and exacting QC standards, we enable our customers to generate high quality genomic data more efficiently, particularly for CNV,” commented Gareth Thomson, OGT’s Director of Genomic Services.

“We are offering our customers the chance to sample Genefficiency for CNV analysis through our pilot study program, which not only allows researchers to make the most of data and resources in disease research, but can also secure a credit of pilot study costs,” he added.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.